Q2 2025 saw improved EBITDA and EBIT losses, but interim revenue declined 27% year-over-year. Cash reserves are low, with urgent funding needs, while the company advances preclinical oncology programs and winds down legacy operations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.